Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in Progressive Supranuclear Palsy
NCT01187888Phase 3Terminated
- Start
- Jan 2010
- Primary completion
- Jun 2012
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rasagiline in progressive supranuclear palsy (PSP) (2 arms). Primary endpoints: Assessment of the need for additional L-DOPA therapy or the need to increase the dose of L-DOPA during the trial at 1 year and Progressive Supranuclear Palsy Rating Scale at 1 year. Started Jan 2010; status: terminated.
02
Drugs
rasagiline
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT01187888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01187888.